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Background: Cohort matching and regression modeling are used in observational studies to 
control for confounding factors when estimating treatment effects. Our objective was to evaluate 
exact matching and propensity score methods by applying them in a 1-year pre–post historical 
database study to investigate asthma-related outcomes by treatment.
Methods: We drew on longitudinal medical record data in the PHARMO database for asthma 
patients prescribed the treatments to be compared (ciclesonide and fine-particle inhaled corti-
costeroid [ICS]). Propensity score methods that we evaluated were propensity score matching 
(PSM) using two different algorithms, the inverse probability of treatment weighting (IPTW), 
covariate adjustment using the propensity score, and propensity score stratification. We defined 
balance, using standardized differences, as differences of <10% between cohorts.
Results: Of 4064 eligible patients, 1382 (34%) were prescribed ciclesonide and 2682 (66%) fine-
particle ICS. The IPTW and propensity score-based methods retained more patients (96%–100%) 
than exact matching (90%); exact matching selected less severe patients. Standardized differences 
were >10% for four variables in the exact-matched dataset and <10% for both PSM algorithms and 
the weighted pseudo-dataset used in the IPTW method. With all methods, ciclesonide was associ-
ated with better 1-year asthma-related outcomes, at one-third the prescribed dose, than fine-particle 
ICS; results varied slightly by method, but direction and statistical significance remained the same.
Conclusion: We found that each method has its particular strengths, and we recommend at 
least two methods be applied for each matched cohort study to evaluate the robustness of the 
findings. Balance diagnostics should be applied with all methods to check the balance of con-
founders between treatment cohorts. If exact matching is used, the calculation of a propensity 
score could be useful to identify variables that require balancing, thereby informing the choice 
of matching criteria together with clinical considerations.
Keywords: asthma, exact matching, propensity score, observational
Background
Observational studies provide important information about the effectiveness and safety 
of therapies in real-life clinical settings. Indeed, many have argued that the results 
of observational studies are an essential complement to the findings of randomized 
controlled trials.1–5 A fundamental limitation of observational studies, however, is 
that treatment assignment is not random. Therefore, demographic and clinical patient 
characteristics that influence doctors’ prescribing choices or that affect treatment out-
comes may systematically differ between patient cohorts being compared, resulting 
in a biased estimation of treatment effects.
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Cohort matching and regression modeling are methods 
used to reduce biases and confounding factors to enable 
comparison between treatment options in observational 
studies. Two commonly used matching methods are exact 
matching and propensity score matching (PSM).6–8 Exact 
matching has the advantage of ensuring that patients are 
paired on key variables of interest; however, increasing the 
number of matching variables to improve the precision of 
matching increases the chance of excluding patients who 
do not match, reducing study sample size and variability of 
the patient population.7 In addition, patients excluded due 
to unavailability of some variables may represent a specific 
population, which would induce a selection bias and limit 
the representativeness of the sample. With PSM, patients 
are matched on a single propensity score representing the 
probability of receiving the exposure of interest given the 
observed baseline characteristics. This method can be espe-
cially useful when treatment cohorts are dissimilar and the 
number of potential confounding factors is large; however, an 
important drawback of PSM is the risk of matching dissimilar 
patients who have similar scores but important differences in 
key variables of interest, especially those that may interact 
with treatment effectiveness.
With both exact matching and PSM, patients who do not 
match are excluded from analysis, which has implications 
for the power of the subsequent comparisons and on repre-
sentativeness of the matched cohorts with regard to the true 
population. Other methods of causal analysis retain the full 
dataset (so no biases are introduced through patient selec-
tion) but use the propensity score in other ways to achieve 
balance between treatment cohorts (ie, not just for matching 
patients). These include the inverse probability of treatment 
weighting (IPTW), covariate adjustment using the propensity 
score, and propensity score stratification.6,8–10
Previous research has evaluated the performance of 
various matching methods. Austin’s research11 compares 
the balance obtained in matched cohorts when using several 
types of propensity score methods, in both real and simulated 
data sets. He does not include exact matching, however, and 
does not investigate the impact of the method choice on the 
primary endpoint of interest. Studies by Wells et al12 and 
Fullerton et al13 compare matching methods in real data 
sets, including exact matching, and discuss the strengths 
and weaknesses of each. Despite these useful studies, it is 
important to gain more evidence in this area, to strengthen the 
conclusions that are drawn from the analyses of one data set 
and to allow investigators to make more informed decisions 
on the design of observational studies.
Our current study contributes to the evidence base by 
comparing matching methods in a real-life data set in which 
we previously investigated asthma-related outcomes in two 
treatment groups. We compared extrafine-particle inhaled 
corticosteroid (ICS) to larger fine-particle ICS – a compari-
son that has been investigated previously.14 We found that 
extrafine-particle ICS was associated with similar or better 
asthma-related outcomes than a larger fine-particle ICS at 
significantly lower prescribed doses.15 In this study, we aim 
to compare the performance of exact matching with that of 
PSM by applying these methods in this historical cohort 
study, including both balance diagnostics and the impact 
on the primary endpoint of the original study. In addition, 
we examine the performance of the propensity score-based 
causal analysis techniques (IPTW, covariate adjustment, and 
stratification).
Methods
We compared analytic methods by applying them to a real-life 
observational study previously reported elsewhere.15
Data source and study design
The previous study used anonymized pharmacy dispensing 
and hospital discharge data drawn from the Dutch PHARMO 
Database Network (September 2005 through December 
2012).16 These data were used to identify patients with asthma 
prescribed extrafine-particle ICS (Alvesco [ciclesonide]) 
or one of two fine-particle ICS (Flixotide [fluticasone] and 
non-extrafine-particle beclomethasone). The aim of the study 
was to investigate the role of particle size in the long-term 
effectiveness of ICS therapy. A 1-year pre–post historical 
cohort analysis of asthma-related outcomes was conducted, 
for patients 12–60 years of age prescribed their first ICS 
therapy as either extrafine-particle or fine-particle ICS. 
Additional criteria required that patients had received two 
or more prescriptions for asthma at any time in addition to 
the first ICS prescription: at least one of these prescriptions 
had to be for ICS during the outcome period (1-year period 
following first ICS prescription), but there had to be no ICS 
prescribed in the baseline period (1-year period preced-
ing first ICS prescription). Patients were excluded if they 
had evidence of any other chronic respiratory disease or if 
they were prescribed long-acting muscarinic antagonists or 
maintenance oral corticosteroids during the baseline period.
The three coprimary endpoints evaluated over 1 outcome 
year were the severe exacerbation rate and the dichotomous 
variables of risk-domain asthma control and overall asthma 
control. We defined severe exacerbations as an asthma-related 
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hospitalization or acute course of oral corticosteroids.17 Risk-
domain asthma control was defined as the absence of severe 
exacerbations, and overall asthma control was defined as 
achieving risk-domain asthma control in addition to receiv-
ing a prescribed mean daily dose of salbutamol ≤200 µg/day. 
Change in therapy was the secondary endpoint.
We conducted the study according to recommended 
standards for observational research, including an a priori 
research plan, study registration, an independent steering 
committee, and commitment to publish.5,18,19
Methods of matching and causal analysis
To compare outcomes between the two treatment cohorts, 
we evaluated exact matching and four approaches using 
the propensity score, namely, PSM, IPTW, covariate adjust-
ment using the propensity score, and propensity score 
stratification.6,10
Exact matching with statistical adjustment for 
residual confounders
Exact matching with statistical adjustment for residual 
confounders (exact matching) has been described in previ-
ous publications from our research team.7,20–23 In brief, we 
first compiled a list of potential matching criteria informed 
by expert clinical advice and previous research experience, 
including those predictive of outcomes and the key baseline 
clinical characteristics differing between unmatched cohorts, 
identified using c2 and Mann–Whitney U tests, as appropriate. 
Our matching criteria for this study were sex, age, baseline 
risk-domain asthma control (controlled/not controlled), 
baseline long-acting β-agonist (LABA) prescription (yes/
no), baseline short-acting β2-agonist (SABA) daily dose, 
baseline leukotriene receptor antagonist prescription (yes/no), 
baseline prescription of antifungals to treat oral candidiasis 
(yes/no), and year of ICS therapy initiation.
Matching criteria were then applied sequentially to pro-
duce two matched cohorts containing all possible pairings; 
bespoke software was used to randomly select final matched 
pairs by eliminating double matches. Endpoints were com-
pared via conditional regression models and adjusted for 
any residual noncollinear baseline confounders and for those 
demographic and baseline variables predictive of the outcome 
through full multivariable analysis.
Propensity score matching
By definition, the propensity score ranges from 0 to 1 and 
is the probability of treatment assignment (in our study, the 
probability of being prescribed ciclesonide), conditional on 
baseline characteristics.6 For PSM, patients are matched on 
one variable, namely, the estimated propensity score or logit 
of the propensity score within a predefined caliper, usually 
employing a 1:1 matching ratio although other ratios can be 
considered, as appropriate to the size and characteristics of 
the available sample.
The list of covariates included in the propensity score 
should include all potential confounders. We selected appro-
priate confounding factors from predictors of outcomes 
identified using multivariable analysis, previous research 
evidence, and differences in demographic and key baseline 
clinical characteristics. The propensity score was estimated 
using a logistic regression model whereby the treatment was 
the dependent variable and the identified covariates were the 
independent variables. The model was stepwise reduced to 
construct a more parsimonious final model to avoid overfit-
ting, which has the potential to inflate variability in the model 
estimates and to increase bias in the presence of unmeasured 
confounders.9,24
We used two different algorithms to match patients in 
the two cohorts in a 1:1 ratio using the propensity score. The 
first algorithm, developed by our research team at Research 
in Real-Life (RiRL; RiRL algorithm), matched patients on 
the logit of the propensity score, initially considering all pos-
sible matches within 0.1 times the pooled standard deviation 
of the logit and then randomly selecting unique matched 
pairings. The second algorithm, developed by Parsons,25 
was the so-called greedy algorithm, which ordered patients 
in the ciclesonide cohort and sequentially matched them on 
the propensity score to the nearest unmatched patient in the 
fine-particle ICS cohort. If >1 unmatched patients in the 
fine-particle ICS cohort were a match, then the matching 
patient was selected at random. Matches were made sequen-
tially with a decreasing level of accuracy (initially matching 
exactly on the propensity score to 5 decimal places reducing 
to 1 decimal place).
After matching on the propensity score, we checked 
balance of the matched cohorts via standardized differences 
to compare mean values and prevalences, respecifying the 
propensity score model until balance was achieved.26 When 
a satisfactory propensity score was identified based on the 
balance assessment of the matched cohorts using the two 
matching methods, the score was used to carry out the 
remaining methods.
The inverse probability of treatment weighting
For the IPTW, propensity scores are used directly as inverse 
weights to estimate average treatment effect (ATE).7,10 This 
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method weights individual patients based on the inverse of 
the probability of their treatment allocation, conditional on 
baseline characteristics, to create a pseudo-dataset in which 
the distribution of potentially confounding variables is 
balanced between the treatment and control groups.8,27 We 
used stabilized weights, which multiply the IPTW by the 
unconditional probability of treatment allocation in order to 
stabilize the variance estimates so that treatment effects and 
their variance can be estimated directly using conventional 
regression methods. Using stabilized weights also preserves 
the original sample size when creating the pseudo-dataset.
Covariate adjustment using the propensity score
Covariate adjustment using the propensity score applies the 
propensity score as a covariate in the regression models to 
adjust the treatment effect.6 Models include the treatment 
cohort and the estimated propensity score as explanatory 
variables, with the estimated propensity score treated as a 
continuous variable. Endpoints are then compared across 
unmatched cohorts. In addition, we adjusted for residual 
confounders to evaluate any potential residual influence of 
baseline predictors.
Propensity score stratification
Rosenbaum and Rubin28 showed that creating 5 propensity 
score subclasses removes at least 90% of the bias in the 
estimated treatment effect of the covariates included in 
the propensity score. Stratification involves the creation of 
a predefined number of strata and then estimation of the 
comparative effects of exposures in the two cohorts within 
each stratum. The stratum-specific estimates of the effects, 
weighted by the proportion of patients within the stratum, are 
then pooled together to obtain the overall treatment effect by 
using the mean of each estimate across the strata. As noted 
by Austin,6 stratification on the propensity score can be con-
ceptualized as a meta-analysis of a set of quasi-randomized 
controlled trials, the latter being the strata.
To apply this method to our dataset, we stratified the 
unmatched treatment cohorts into quintiles by propensity 
score before outcome evaluation.
More details about the above methods can be seen in the 
“Additional methods” section of the Supplementary materials.
Comparison between exact matching and 
propensity score methods
We compared the performance of exact matching and propen-
sity score methods by evaluating the following three criteria: 
1) the balance obtained using standardized differences to 
compare mean values and prevalences of baseline variables 
(for exact matching, PSM, and IPTW); 2) modeled outcome 
results (for all methods); and 3) the number of patients lost 
during matching (with exact matching and PSM).
Standardized differences were calculated using a macro 
written in SAS statistical software, developed by Yang and 
Dalton and available via the website of the Lerner Research 
Institute.29 Using standardized differences, we considered 
balance as being achieved for differences lying within a 10% 
window, which has been used in the literature as the definition 
of a negligible difference.6
Conventional regression models were used to estimate 
and compare the outcomes between the unmatched treat-
ment cohorts and those constructed using IPTW methods. 
Conditional regression models were used to estimate and 
compare the outcomes between matched cohorts. Results 
included rate ratios (RRs) and odds ratios (ORs) with 95% 
confidence intervals (CIs), first calculated using only the 
matching or propensity score method and then additionally 
adjusted for any residual confounders.
For the exact-matched analyses, the results for the 
dichotomous outcomes of risk-domain and overall asthma 
control differed slightly from previously published results 
because this study used PROC LOGISTIC (rather than PROC 
GENMOD with a binomial distribution and logit link) for 
these analyses. This was because PROC GENMOD cannot 
be used for a stratified analysis (by propensity score) and so, 
for consistency and to allow comparison, PROC LOGISTIC 
was used throughout.
Analyses were conducted with SAS v9.3 (SAS Insti-
tute, Marlow, Buckinghamshire, UK) and SPSS v22 (IBM 
 Corporation, Armonk, NY, USA). Statistical significance 
was set at P<0.05 and trends at P<0.10.
Ethical approval
The study was approved by the PHARMO compliance and 
governance board – the independent Compliance Committee 
STIZON/PHARMO Institute. This committee is approved 
by the Dutch Data Protection Authority to control the provi-
sion of PHARMO data for scientific research. Due to the 
anonymization of the data, formal patient consent was not 
required, upon approval of the research question and the 
methods planned to analyze the data.
Results
Sample sizes and power
Of 4064 eligible patients identified in the database during 
the study period, 1382 (34%) were prescribed extrafine-
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particle ciclesonide and 2682 (66%) fine-particle ICS. 
Hence, this was the size of the original, unmatched data 
set, to which the matching methods were applied (creat-
ing data subsets). The mean (standard deviation) age was 
43 (13) years in the ciclesonide cohort and 38 (15) in the 
fine-particle ICS cohort; 36% of patients in each cohort 
were male (Table 1).
Of the 1382 unmatched patients initiating ICS therapy as 
ciclesonide, 1244 (90%) were retained using exact matching, 
and 1321 and 1323 (both 96%) were retained using PSM 
(RiRL and greedy algorithms, respectively). According to a 
posteriori power  calculations, these sample sizes all provided 
adequate power: using the unmatched proportions achieving 
risk-domain asthma control (0.897 and 0.850; OR 1.537) and 
a two-cohort c2 test with two-sided significance with α of 
0.05, unmatched analyses were powered at 99%; the exact 
matching comparison was powered at 93%; and the PSM 
comparisons were both powered at 94% to detect a difference 
between cohorts in risk-domain asthma control.
Cohort matching and representation of 
the full population
A list of 12 covariates to use for the propensity score estima-
tion was identified after excluding seven collinear variables 
and three variables not contributing to the final model 
(Table  2). Baseline daily SABA dose and evidence of gastro-
esophageal reflux disease (GERD) both strongly influenced 
the propensity score (Table S1 for correlation coefficients).
Table 1 Baseline demographic and clinical characteristics of patients
Patient 
characteristics
Unmatched Exact matching Propensity score matching Stabilized IPTW 
pseudo-datasetRiRL algorithm Greedy algorithm
Ciclesonide 
(n=1382)
FP ICS 
(n=2682)
Ciclesonide 
(n=1244)
FP ICS 
(n=1244)
Ciclesonide 
(n=1321)
FP ICS 
(n=1321)
Ciclesonide 
(n=1323)
FP ICS 
(n=1323)
Ciclesonide 
(n=1380)
FP ICS 
(n=2683)
Sex, male 492 (36) 969 (36) 436 (35) 436 (35) 470 (36) 493 (37) 478 (36) 461 (35) 487 (35) 961 (36)
Age, mean (SD) 43 (13) 38 (15)a 43 (13) 43 (13)b 42 (13) 43 (13) 43 (13) 43 (13) 40 (14) 39 (14)
Comorbidityc
 Rhinitis 612 (44) 1021 (38)d 539 (43) 469 (38)b 567 (43) 568 (43) 569 (43) 560 (42) 554 (40) 1076 (40)
 Eczema 427 (31) 744 (28)d 381 (31) 358 (29) 407 (31) 386 (29) 412 (31) 400 (30) 406 (29) 785 (29)
 GERD 572 (41) 771 (29)d 504 (41) 420 (34)b 529 (40) 521 (39) 535 (40) 493 (37)b 463 (34) 889 (33)
 Thrush 20 (1.4) 21 (0.8)d 2 (0.2) 2 (0.2) 16 (1.2) 14 (1.1) 16 (1.2) 15 (1.1) 13 (1.0) 26 (1.0)
Acetaminophen 
scripta
24 (1.7) 65 (2.4) 23 (1.8) 33 (2.7) 23 (1.7) 23 (1.7) 23 (1.7) 22 (1.7) 33 (2.4) 58 (2.2)
Year of ICS 
initiation,  
median (IQR)
2009  
(2007–2010)
2008a 
(2007–
2009)
2009  
(2007–2010)
2009 
(2007–
2010)
2009  
(2007–2009)
2009 
(2008–2010)
2009  
(2007–2009)
2009 
(2007–
2010)
2008  
(2007–2009)
2008 
(2007–
2009)
≥1 acute OCS 
prescription
136 (10) 332 (12)a 99 (8) 112 (9) 129 (10) 128 (10) 130 (10) 127 (10) 155 (11) 309 (12)
Mean daily SABA dose (µg/d)
 0 989 (72) 1519 (57)d 902 (73) 902 (73) 934 (71) 930 (70) 938 (71) 945 (71) 847 (61) 1653 (62)
 1–100 294 (21) 759 (28) 269 (22) 269 (22) 289 (22) 274 (21) 287 (22) 286 (22) 362 (26) 695 (26)
 101–200 65 (5) 234 (9) 50 (4) 50 (4) 64 (5) 79 (6) 64 (5) 59 (5) 107 (8) 200 (8)
 >200 34 (3) 170 (6) 23 (2) 23 (2) 34 (3) 38 (3) 34 (3) 33 (3) 63 (5) 134 (5)
LABA 44 (3.2) 68 (2.5) 8 (0.6) 8 (0.6) 38 (2.9) 33 (2.5) 40 (3.0) 36 (2.7) 34 (2.5) 71 (2.7)
LTRA 40 (2.9) 21 (0.8)d 3 (0.2) 3 (0.2) 22 (1.7) 18 (1.4) 19 (1.4) 18 (1.4) 20 (1.5) 39 (1.4)
≥1 hospital 
admission
30 (2.2) 20 (0.7)d 24 (1.9) 6 (0.5)b 16 (1.2) 20 (1.5) 13 (1.0) 18 (1.4) 18 (1.3) 35 (1.3)
≥1 severe 
exacerbations
159 (12) 348 (13) 117 (9) 117 (9) 139 (11) 144 (11) 138 (10) 141 (11) 167 (12) 339 (13)
Risk-domain 
asthma control 
1223 (89) 2334 (87) 1127 (91) 1127 (91) 1182 (90) 1177 (89) 1185 (90) 1182 (89) 1213 (88) 2344 (87)
Overall control 1195 (87) 2194 (82)a 1105 (89) 1105 (89) 1154 (87) 1145 (87) 1157 (88) 1155 (87) 1159 (84) 2233 (83)
Notes: Data are n (%) unless otherwise noted. Smoking status and body mass index are not reported as data were available for only 1.5% and 7% of patients, respectively. 
aP<0.001 Mann–Whitney for comparison between cohorts. bP<0.05 conditional logistic regression for comparison between cohorts. cEvidence of comorbidities defined as 
recorded ICD-9 or ICD-10 code (International Classification of Disease) or via appropriate prescriptions during baseline and/or outcome year: nasal corticosteroids for 
rhinitis, proton pump inhibitors for GERD, topical corticosteroids for eczema, and topical oral antifungal medication for thrush. dP<0.05 χ2 for comparison between cohorts. 
Abbreviations: FP ICS, fine-particle inhaled corticosteroid; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; IPTW, inverse probability of treatment 
weighting; IQR, interquartile range; LABA, long-acting beta-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; RiRL, Research in Real-Life; SABA, 
short-acting β2-agonist; SD, standard deviation.
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Baseline patient characteristics for unmatched cohorts 
and the cohorts selected by exact matching and propensity 
score methods are depicted in Table 1. In the unmatched 
population, patients in the ciclesonide cohort received fewer 
baseline prescriptions for SABA but more for proton pump 
inhibitors (for treating GERD) than patients in the fine-
particle ICS cohort. All matched samples tended toward the 
characteristics of the unmatched ciclesonide cohort.
In the exact-matched dataset, standardized differences 
were outside the 10% corridor for prescriptions for aller-
gies (both measured on the interval scale and categorized), 
hospital admissions for asthma, evidence of rhinitis, and 
evidence of GERD (Figure 1). Exact matching selected 
the sample with least severe asthma: 91% recorded no 
exacerbations at baseline, compared with 87%–88% in the 
unmatched dataset and 89%–90% in the datasets matched 
on propensity score.
For the PSM datasets produced using the RiRL and 
greedy algorithms (Table 1), all standardized differences were 
within the range of −0.1 to 0.1 (ie, absolute values within 
10%) for both matching algorithms (Figure 1).
Using the IPTW method, a pseudo-dataset was created 
with sample size of 4063 (1380 and 2683 patients in cicle-
sonide and fine-particle ICS cohorts, respectively). The two 
cohorts were well balanced, and overall characteristics of 
the full unmatched population were retained (Table 1). All 
standardized differences were within the −0.1 to 0.1 range 
for the weighted pseudo-dataset, including those for the two 
variables where there remained a statistically significant dif-
ference at baseline (Figure 1).
For the unmatched and all matched populations, and 
the IPTW pseudo-dataset, the median (interquartile range) 
prescribed dose of ciclesonide at initiation was 160 µg/day 
(160–160) whereas that of fine-particle ICS (fluticasone-
equivalent dose) was 500 µg/day (250–500; P<0.001).
Evaluation of treatment effects by study 
endpoint
Unadjusted results for study endpoints are presented in 
Table S2; unadjusted and adjusted RRs and ORs with each 
method are presented in Figure 2A–D. Details of the vari-
ables used to adjust the models are listed in the footnotes of 
Figure 2A–D.
Results for severe exacerbations showed a reduction in 
the RR for the treatment effect relative to the unmatched, 
unadjusted results (RR: 0.73; 95% CI: 0.58–0.90) using 
all analysis methods except for stratification by propensity 
score, which could not be used for this endpoint (see the 
“Additional results” section in Supplementary materials for 
explanation) and PSM with RiRL algorithm, which did not 
require adjusting for evidence of GERD (Table 3; Figure 2A). 
In the other matched datasets, the reduction in the RR was a 
result of adjustment for evidence of GERD, as the proportion 
Table 2 Demographic and baseline covariates included in the 
propensity score estimation
Covariates included
Initial list of covariates 
examined (22)
Non-collinear 
covariates 
included (15)
Variables 
contributing to the 
model (12)
Agea X X
Sex X
Year of ICS initiationa X X
Time from first asthma  
prescriptiona
Evidence of rhinitis (Y/N)a,b X X
Evidence of eczema (Y/N)a,b X X
Evidence of GERD (Y/N)a,b X X
Evidence of cardiac  
disease or hypertension  
(Y/N)a,b 
Prescriptions for beta  
blockers (Y/N)a,c
Prescriptions for NSAIDs  
(Y/N)c
Prescriptions for  
paracetamol (Y/N)c
X X
Prescriptions for tricyclic  
agents (Y/N)c
X
Prescriptions for statins  
(Y/N)c
X
Number of prescriptions  
for allergies (categorized)c
Number of prescriptions  
for acute oral  
corticosteroids (0/≥1)a
X X
Number of prescriptions  
for SABA (categorized)a
Number of SABA  
inhalers (categorized)a
Average daily SABA dose  
(categorized)a,d
X X
LABA prescription (Y/N) X X
LTRA prescription (Y/N)a X X
Hospital admissions for  
asthma (Y/N)a
X X
Evidence of thrush (Y/N)a,b X X
Notes: aP<0.05 for comparison between cohorts (for beta blockers 0.05<P<0.10). 
bEvidence of comorbidities defined as recorded ICD-9 or ICD-10 code or via 
appropriate prescriptions during baseline and/or outcome year: nasal corticosteroids 
for rhinitis, topical corticosteroids for eczema, proton pump inhibitors for GERD, 
topical oral antifungal medication for thrush, and cardiac glycosides, antihypertensive 
agents, diuretics, beta blocking agents, calcium channel blockers, and ACE 
(angiotensin-converting enzyme) inhibitors for cardiac disease/hypertension. cOne 
or more prescription(s) received during the baseline year or at the initiation date 
of ICS therapy. dCalculated as (count of inhalers × doses in pack/365) × µg strength.
Abbreviations: GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; 
NSAIDs, nonsteroidal anti-inflammatory drugs; LABA, long-acting β2-agonist; LTRA, 
leukotriene receptor antagonist; SABA, short-acting β2-agonist; Y/N, yes/no.
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of patients with evidence of GERD remained significantly 
higher in the ciclesonide cohort than the fine-particle ICS 
cohort in those datasets.
For risk-domain asthma control, the adjusted ORs varied 
from 1.46 (PSM with RiRL algorithm) to 1.66 (exact match-
ing and stratification). Both estimates using PSM lowered 
the OR from the unmatched, unadjusted whereas all other 
methods increased the OR fairly consistently to 1.63–1.66, 
when adjusted (Table 3; Figure 2B). CI widths for adjusted 
estimates varied from 0.68 (IPTW) to 0.88 (exact matching).
For overall asthma control, adjusted ORs varied between 
analysis methods from 1.80 (PSM with RiRL algorithm) to 
2.21 (IPTW), all lower than the unmatched, unadjusted OR 
(2.29; 1.93–2.71; Table 3; Figure 2C). For PSM with RiRL 
algorithm, the adjusted result was lower than the unadjusted, 
driven by an adjustment for SABA use and negligible 
 difference in evidence of GERD between cohorts, which 
drove the increase in adjusted ORs when using other methods.
Results of analyses of change in therapy were quite 
consistent across analysis methods, ranging from 0.69 
(adjusted/unadjusted OR for PSM with RiRL algorithm) to 
0.74 (weighted OR for IPTW). CIs were marginally greater 
using the matched datasets (Table 3; Figure 2D).
Table 3 summarizes our findings with regard to the use 
of each method of analysis both generally and specific to 
this study.
Discussion
We compared cohort matching and other methods of causal 
analysis and found that all methods – exact matching, PSM, 
IPTW, covariate adjustment, and stratification – produced 
similar results, namely, that ciclesonide, at much lower 
prescribed doses, was associated with better asthma-related 
outcomes than fine-particle ICS. The results varied slightly 
by method, depending on the patient subgroup selected, 
absolute and relative asthma severity, and residual differ-
ences between cohorts. However, the direction and  statistical 
significance of the results remained comparable with all 
methods. Standardized differences lay outside of the 10% 
corridor in the exact-matched dataset for several variables, 
Figure 1 Standardized differences between cohorts in key baseline characteristics for the unmatched dataset, exact matching, propensity score matching, and the pseudo-
dataset weighted by the stabilized IPTW. Absolute standardized differences in the unmatched dataset extended to 0.375, and for the exact-matched dataset, standardized 
differences were outside of the ±0.1 interval defining balance for allergy prescriptions, asthma-related hospital admissions, evidence of rhinitis, and evidence of GERD. All 
standardized differences were within ±0.1 for the datasets matched on propensity score and the pseudo-dataset weighted by IPTW.
Abbreviations: ICS, inhaled corticosteroid; GERD, gastroesophageal reflux disease; IPTW, inverse probability of treatment weighting; LABA, long-acting β2-agonist; LTRA, 
leukotriene receptor antagonist; NSAIDs, nonsteroidal anti-inflammatory drugs; RiRL, Research in Real-Life; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic 
antagonist; Y/N, yes/no.
Year of ICS initiation (categorized)
Year of ICS initiation
Tricyclics prescription (Y/N)
Time from 1st asthma script to ICS initiation (categorized)
Theophylline prescription (Y/N)
Stalin prescription (Y/N)
SAMA prescription (Y/N)
SABA prescription (Y/N)
Risk-domain asthma control
Acetaminophen (paracetamol) use (Y/N)
Overall asthma control
Number of prescriptions for SABA (categorized)
Number of prescriptions for SABA
Number of prescriptions for allergies (categorized)
Number of prescriptions for allergies
Number of acute courses of oral steroids (categorized)
Number of acute courses of oral steroids
Number of SABA inhalers (categorized)
Number of SABA inhalers
NSAIDs prescription (Y/N)
LTRA prescription (Y/N)
LABA prescription (Y/N)
Asthma-related hospital admissions
Sex
Exacerbations (categorized)
Evidence of rhinitis
Evidence of oropharyngeal candidiasis
Evidence of gastroesophageal reflux disease
Evidence of eczema
Evidence of cardiac disease / hypertension
Beta blocker prescription (Y/N)
Average daily SABA dose (categorized)
Average daily SABA dose
Age group
Age
–0.4 –0.3 –0.2 –0.1 0.0
Standardized difference
Dataset
Unmatched
Exact matching
RiRL algorithm
IPTW
Greedy algorithm
0.1 0.2 0.3 0.4
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Figure 2 (Continued)
Method N Ref: Fine-particle ICS Rate ratio (95% CI) for
severe exacerbations
0.73 (0.58–0.90)
0.69 (0.55–0.86)
0.69 (0.55–0.85)a
0.73 (0.58–0.90)
0.69 (0.55–0.86)
0.69 (0.56–0.85)b
0.71 (0.55–0.91)
0.69 (0.53–0.89)c
0.71 (0.55–0.91)c
0.73 (0.56–0.93)
0.73 (0.57–0.93)d
0.71 (0.55–0.92)
4064
4064
4064
4064
2488
2646
2642
Unmatched, unadjusted
Unadjusted
Adjusted
0.3 0.5 1.0 2.0 3.0
Adjusted for PS
Stratified by PS (quintiles)
IPTW (stabilized)
Exact matching
PSM – greedy algorithm
PSM – RiRL algorithm
Method
A
B
N Ref: Fine-particle ICS Odds ratio (95% CI) for
risk-domain asthma control
1.54 (1.25–1.88)
1.62 (1.31–2.00)
1.65 (1.33–2.05)a
1.59 (1.29–1.97)
1.66 (1.33–2.06)b
1.60 (1.31–1.97)
1.63 (1.33–2.01)c
1.60 (1.24–2.06)
1.66 (1.28–2.16)d
1.45 (1.14–1.83)
1.48 (1.16–1.87)d
1.50 (1.19–1.90)
1.46 (1.15–1.86)d
4064
4064
4064
4064
2488
2646
2642
0.3 0.5 1.0 2.0 3.0
Unadjusted
Adjusted
Unmatched, unadjusted
Adjusted for PS
Stratified by PS (quintiles)
IPTW (stabilized)
Exact matching
PSM – greedy algorithm
PSM – RiRL algorithm
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Figure 2 Comparison of outcomes using exact matching and propensity score methods.
Notes: (A) Results for comparison of exacerbation rates using exact matching and propensity score methods. aAdjusted for propensity score and baseline exacerbations 
(0/≥1). bAdjusted for age group and baseline exacerbations (0/≥1). cAdjusted for evidence of GERD and baseline exacerbations (0/≥1). dAdjusted for baseline exacerbations 
(0/≥1). Comparison of rate ratios (95% CIs) for severe exacerbation rates estimated using a Poisson regression model. (B) Results for comparison of risk-domain asthma 
control using exact matching and propensity score methods. aAdjusted for propensity score and baseline RDAC status. bAdjusted for the evidence of GERD and baseline 
RDAC status. cAdjusted for age group, evidence of GERD, and time from first asthma prescription. dAdjusted for evidence of GERD. Odds ratios compare ciclesonide versus 
the fine-particle ICS cohort (the latter set at odds=1.0). Odds ratios (95% CIs) for risk-domain asthma control estimated using a logistic regression model. (C) Results for 
comparison of overall asthma control using exact matching and propensity score methods. aAdjusted for propensity score, baseline RDAC status, and time from first asthma 
prescription. bAdjusted for evidence of GERD, leukotriene receptor antagonist use, baseline average daily SABA dose (categorized) and baseline RDAC status. cAdjusted 
for age group, evidence of GERD, baseline average daily SABA dose (categorized) and baseline RDAC status. dAdjusted for evidence of GERD and baseline overall asthma 
control. eAdjusted for evidence of GERD, baseline average daily SABA dose (categorized as 0/1–100/101–200/>200 µg) and baseline RDAC status. Odds ratios compare 
ciclesonide versus the fine-particle ICS cohort (the latter set at odds =1.0) and were estimated using a logistic regression model. (D) Results for comparison of change in 
therapy using exact matching and propensity score methods. aAdjusted for evidence of rhinitis and evidence of GERD. bAdjusted for evidence of GERD. cAdjusted for evidence 
of rhinitis. Odds ratios compare ciclesonide versus the fine-particle ICS cohort (the latter set at odds=1.0). Odds ratios (95% CIs) for change in therapy estimated using a 
logistic regression model.
Abbreviations: CI, confidence interval; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; IPTW, inverse probability of treatment weighting; PS, propensity 
score; PSM, propensity score matching; RDAC, risk-domain asthma control; RiRL, Research in Real-Life.
Ref: Fine-particle ICS
Ref: Fine-particle ICS
Odds ratio (95% CI) for
overall asthma control
Odds ratio (95% CI) for
change in therapy
2.29 (1.93–2.71)
0.72 (0.62–0.83)
0.71 (0.61–0.83)
0.72 (0.62–0.84)
0.72 (0.62–0.83)a
0.74 (0.64–0.85)
0.71 (0.60–0.85)
0.70 (0.59–0.83)a
0.73 (0.62–0.86)
0.72 (0.61–0.85)b
0.69 (0.58–0.81)c
0.69 (0.59–0.82)
2.03 (1.70–2.43)
2.04 (1.71–2.45)a
2.07 (1.71–2.47)
2.20 (1.83–2.64)b
2.07 (1.75–2.45)
2.21 (1.86–2.64)c
2.02 (1.63–2.51)
2.06 (1.66–2.57)d
2.01 (1.65–2.46)
2.17 (1.75–2.69)e
1.88 (1.54–2.29)
1.80 (1.45–2.24)e
N
4064
4064
4064
4064
2488
2646
2642
N
4064
4064
4064
4064
2488
2646
2642
0.3 0.5 1.0 2.0 3.0
Method
Unmatched, unadjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Adjusted for PS
Stratified by PS (quintiles)
IPTW (stabilized)
Exact matching
PSM – greedy algorithm
PSM – RiRL algorithm
Method
Unmatched, unadjusted
Adjusted for PS
Stratified by PS (quintiles)
IPTW (stabilized)
Exact matching
PSM – greedy algorithm
PSM – RiRL algorithm
C
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Table 3 Comparative characteristics of causal analysis methods tested for comparison between extrafine ciclesonide and larger fine-
particle ICS in real-life patients with asthma from the PHARMO database
Methods Advantages Limitations Measured effect
Exact matching Patients are paired on defined  
key variables of interest
Some variables may remain unbalanced  
between cohorts
Average treatment effect for a 
typical treated patient
Fewer remaining patients
May select a sample not representative of  
the true population (in this study selected  
patients with slightly less severe asthma)
Propensity score  
matching
All variables of interest are  
well balanced (appropriate for  
situations with high numbers of 
confounders)
Average treatment effect for a 
typical treated patient
In this study preserved close  
to full sample size (almost no  
excluded patients)
Inverse probability of 
treatment weighting
Preserves sample size (no  
excluded patients)
Average treatment effect at the 
population level
Covariate adjustment  
using propensity score
Preserves sample size (no excluded 
patients)
Average treatment effect at the 
population level
Propensity score 
stratification
Preserves sample size (no excluded 
patients)
PSS: inappropriate for count data outcomes  
modeled with Poisson
Average treatment effect at the 
population level
Notes: The term balance refers to standardized differences >10%. All methods provided similar results in terms of direction and statistical significance, in favor of the 
extrafine ciclesonide treatment. All results remained largely unchanged after adjustment for residual confounders.
Abbreviations: ICS, inhaled corticosteroid; PSS, propensity score stratification.
whereas all standardized differences were <10% for both 
PSM algorithms and the weighted pseudo-dataset.
Exact matching retained the lowest number of patients, 
hence had the lowest power and was potentially the least likely 
to be representative of the full population. However, adjusting 
for residual confounders after matching made only modest 
differences, particularly in the analysis of overall asthma 
control for which the adjustments in some other methods 
made quite large differences. This suggests that exact match-
ing was effective in reducing confounding.
With PSM, both algorithms used to match on the propensity 
score (RiRL matching and greedy algorithms) retained similar 
numbers of patients. The pseudo-dataset generated by IPTW 
preserved almost all of the original sample size. For both PSM 
methods, and the IPTW, adjusting for residual confounders 
after matching again made only modest differences for most 
of the outcomes. However, there were larger differences after 
adjustment for residual confounders in the analysis of overall 
asthma control. This suggests that such confounding is impor-
tant to investigate, rather than relying on the matching alone.
Covariate adjustment using the propensity score gave 
results consistent with other methods for all endpoints, and 
further adjustment had limited effects. Stratification by 
propensity score was not a suitable method for analyzing 
exacerbation rates as a primary endpoint but was suitable 
for the dichotomous endpoints.
In a prior case study comparing propensity score methods, 
Austin30 reported that systematic differences between treat-
ment cohorts were reduced more by PSM and IPTW than 
by covariate adjustment using the propensity score or strati-
fication by propensity score. Recent studies have compared 
PSM and coarsened exact matching, a newer method that 
uses stratification followed by exact matching of cohorts for 
key variables influencing study endpoints with strata-based 
weighting according to the proportion of patients in each 
stratum.12,31–33 The matching methods produced similar results 
in these studies; however, Wells et al12 reported that coarsened 
exact matching retained more patients and achieved better 
balance between cohorts than PSM.
Our findings suggest that exact matching criteria could 
be informed by a propensity score calculation in addition to 
the usual clinical considerations. An alternative is to match 
on the propensity score following exact matching on key 
clinical characteristics.34–36 For example, Kozma et al36 in 
their study of health care resource use and costs for chronic 
obstructive pulmonary disease applied exact matching on 
four variables (sex, south region, pneumonia, and ischemic 
heart disease) followed by nearest available Mahalanobis 
distance matching within calipers defined by propensity 
scores. With any matching method, we recommend that 
standardized  differences should be used, in conjunction with 
statistical testing, to assess the balance of treatment groups 
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at baseline.6,9,11,26 Other proposed methods of assessing bal-
ance may also be appropriate, including the z-difference or 
a weighted summary balance measure accounting for the 
strength of association of each covariate with the outcome.37,38
Another consideration when choosing matching and 
analytic methods is whether the ATE on the treated (ATT) 
or the ATE is of greater interest. The ATT, calculable using 
exact matching or PSM, is defined as the average response to 
treatment for a sample of individuals who are assigned treat-
ment (in our study, “typical” patients prescribed ciclesonide). 
Instead, the ATE, which is calculable using IPTW, covariate 
adjustment for the propensity score, or stratification by the 
propensity score, is the average response to treatment for a 
random sample from a population.
Our findings suggest that the most appropriate matching 
method for a particular study should be selected according 
to study objectives, endpoints, and the available dataset. For 
example, if a treatment is prescribed primarily to a certain 
demographic group, the ATT may be more relevant than 
considering the treatment effect (by extrapolation) across 
other demographic groups (ATE). However, if the treat-
ment effect across all demographic groups is of interest but 
limited data are available, the ATE would be more relevant. 
As noted above, our analyses using the matched datasets 
estimated the ATT, whereas the analysis methods that used 
the full unmatched dataset (IPTW, covariate adjustment, 
stratification) estimated the ATE. The proximity of the ATT 
to the ATE depends on the amount of overlap between the two 
cohorts in the unmatched dataset (in this case, ciclesonide 
and fine-particle ICS cohorts).
Limitations
Our methodological exercise has some limitations. The 
data in PHARMO reflect the real-life prescribing practices 
of Dutch physicians. As such, the individual decision to 
prescribe ciclesonide or a fine-particle ICS such as flutica-
sone, or no ICS, to a patient with asthma at any given time 
is likely variable. While we matched on measured baseline 
variables, the possibility of differences in unmeasured vari-
ables remains, and we cannot rule out residual confounding.
Another limitation of the present methodology study 
is inherent to the design of the original study on which the 
analyses were based: namely, it has to be assumed that a pre-
scription identified in pharmacy data reflects the medications 
actually taken by the patient. However, a difference in adher-
ence between treatment cohorts cannot be excluded and may 
have introduced bias into the comparison between cohorts.
Finally, the extrapolation of prescribing habits of Dutch 
physicians to other settings should be applied with caution.
Conclusion
The results of this study suggest that stratification by propen-
sity score is not a suitable method where exacerbation rates 
are a primary endpoint. Otherwise, our findings suggest that 
all other methods (exact matching, PSM, IPTW, and covariate 
adjustment using the propensity score) have their particular 
strengths; and the most suitable method to fulfill study aims 
with regard to the dataset should be selected while factoring 
in study endpoints, relevance of ATT versus ATE, the overlap 
of treatment cohorts in the available data, and the estimated 
power of each method. Balance diagnostics should be applied 
with all methods to check the balance of confounders between 
treatment cohorts. Moreover, we recommend that at least two 
methods be applied for each matched cohort study to evaluate 
the robustness of the findings. If exact matching is used, the 
calculation of a propensity score could be useful to identify 
variables that require balancing, thereby to inform the choice 
of matching criteria together with clinical considerations.
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(particularly in the analysis of overall asthma control for 
which adjustments in some other methods made quite large 
differences), suggesting that the matching was effective in 
reducing confounding. All models were adjusted for evidence 
of gastroesophageal reflux disease (GERD). This was not a 
matching variable and significant differences (41% vs. 34% 
in ciclesonide vs. fine-particle cohorts) remained at baseline 
after matching; standardized differences were in excess of 
10%. Calculation of the propensity score showed this to be a 
strong predictor of treatment allocation, which maybe could 
have been improved by using the propensity score to influ-
ence choice of exact matching criteria. It would have been 
interesting to repeat the exact matching process, matching 
also on evidence of GERD, although the gain in balance 
across treatment arms would need to be weighed against a 
further loss in sample size and therefore power.
Propensity score matching
A list of 12 covariates to use for the propensity score esti-
mation was identified after excluding 7 collinear variables 
and 3 variables not contributing to the final model (Table 2). 
Baseline daily short-acting β2-agonist (SABA) dose and 
evidence of GERD both strongly influenced the propensity 
score (see Table S1 for correlation coefficients).
Both algorithms used to match on the propensity score 
(Research in Real-Life [RiRL] matching algorithm and 
greedy algorithm) retained similar numbers of patients (2642 
and 2646, respectively). In the PSM dataset produced using 
the RiRL algorithm, there were no significant differences 
Table S1 Correlation coefficients between the propensity score 
and its components, ranked in order of absolute magnitude
Variable Correlation 
coefficient
Average daily SABA dose (categorized)
−0.532
Evidence of GERD (Y/N) 0.446
Year of ICS initiation 0.291
LTRA prescription (Y/N) 0.288
Baseline asthma-related hospital admissions  
(categorized)
0.215
Evidence of rhinitis (Y/N) 0.210
Number of prescriptions for acute oral  
corticosteroids (categorized)
−0.132
Evidence of eczema (Y/N) 0.116
Evidence of thrush (Y/N) 0.110
Prescriptions for paracetamol (Y/N)
−0.078
LABA prescription (Y/N) 0.066
Sex
−0.018
Abbreviations: GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; 
LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; SABA, short-
acting β2-agonist; Y/N, yes/no.
Supplementary materials
Additional methods
Methods of matching and causal analysis
We evaluated exact matching, propensity score match-
ing (PSM), the inverse probability of treatment weighting 
(IPTW), covariate adjustment using the propensity score, and 
propensity score stratification. The IPTW, covariate adjust-
ment, and stratification methods differ from PSM in that they 
retain the full dataset (so no biases are introduced through 
patient selection) but use the propensity score in other ways 
to achieve balance (ie, not just for matching patients).
Propensity score matching
For PSM, patients are matched on one variable, the estimated 
propensity score or logit of the propensity score within a 
predefined caliper, usually employing a 1:1 matching ratio 
although other ratios can be considered, as appropriate to the 
data. Because the precision of the propensity score is based on 
the inclusion of potential confounders into the statistical regres-
sion model used for its estimation, the true propensity score is 
not known. As a consequence, residual confounders can persist 
even after the application of the propensity score approaches.
Therefore, after applying PSM, we conducted a balance 
assessment by repeating the baseline analysis to ensure that 
the balance between cohorts was obtained and to test whether 
the propensity score model was adequately specified. We 
respecified the propensity score model by adding more vari-
ables (based on previous research experience), interactions, 
and non-linear terms until appropriate balance was obtained. 
Balance between cohorts was evaluated by comparing sum-
mary statistics of baseline variables via comparison of P val-
ues, using conditional logistic regression with significance set 
at P<0.05, and via use of standardized differences to compare 
mean values and prevalence of baseline variables; balance 
was considered achieved for differences lying within a 10% 
window. Standardized differences were calculated using a 
SAS macro developed by Yang and Dalton and available via 
the website of the Lerner Research Institute.1
Additional results
Exact matching
Exact matching retained the fewest patients (2488) and so 
was the lowest powered and least likely to be representative 
of the full population. Indeed, patients in the ciclesonide 
cohort selected for matching were marginally less severe than 
the overall unmatched population. Adjustment for residual 
confounders after matching made only modest differences 
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between cohorts in baseline variables at the 5% level. A 
trend (P<0.10) was recorded for shorter duration of asthma 
(P=0.083), lower mean daily SABA doses (P=0.096 on the 
ratio scale), and less short-acting muscarinic antagonist use 
(P=0.056) in the ciclesonide cohort as compared with the 
fine-particle inhaled corticosteroid cohort. Using the greedy 
algorithm, there was one significant difference between 
cohorts at the 5% level (higher incidence of GERD in the 
ciclesonide cohort; P=0.022) and a trend (P=0.094) for 
shorter duration of asthma in the ciclesonide cohort.
Adjustment for residual confounders after matching 
made only modest differences except in the analysis of 
overall asthma control, suggesting that the matching was, 
generally, effective in reducing confounding. Unadjusted and 
adjusted odds ratios (ORs) for risk-domain asthma control 
were lower than the unmatched and unadjusted, whereas ORs 
were higher using all other methods, which likely reflects the 
sample of patients selected. Furthermore, the adjusted ORs 
for risk-domain and overall asthma control were lower than 
the unadjusted ORs when using PSM with RiRL algorithm, 
whereas adjustments to the model in all other analysis meth-
ods increased the ORs. This apparent anomaly was driven by 
the magnitude of the residual baseline difference in evidence 
of GERD between cohorts (negligible difference using the 
RiRL algorithm, significant differences in other datasets), 
further confirming that models and results were sensitive to 
the sample selected, including both the absolute and relative 
severity of the patients and residual baseline and standardized 
differences between cohorts in key variables.
Inverse probability of treatment weighting
Stabilized weights – which multiply the IPTW by the 
unconditional probability of treatment allocation – were 
used to create a pseudo-dataset with sample size of 4063, so 
near-preserving the sample size of the original data. There 
were statistically significant differences between cohorts 
in mean daily SABA doses and prescriptions for allergies 
when measured on the ratio/interval scale, but cohorts were 
balanced when these variables were categorized; there were 
no other significant differences between treatment arms at 
the 5% level (Table 1 in the main paper). There was a trend 
(P=0.062) for a different distribution of severe exacerbations 
across treatment arms with greater proportions of patients in 
the ciclesonide cohort in the 0 and ≥2 categories. The largest 
differences were seen in baseline exacerbations (categorized) 
(0.08) and age group (0.09). Standardized differences were 
within the −0.1 to 0.1 range for the weighted pseudo-dataset, 
including the two variables where there remained a statisti-
cally significant difference at baseline; however, as Austin2 
notes, statistical significance is not the recommended method 
to assess balance and the standardized differences confirmed 
that an acceptable balance was achieved.
Adjustment for residual confounders made only minimal 
differences to the exacerbation and risk-domain asthma 
control endpoints, and no difference to the change in therapy 
endpoint, suggesting that the weighting was effective in 
reducing confounding. Adjusting for residual confounders 
increased the OR for overall asthma control, driven mainly by 
the residual difference in SABA use between cohorts. Over-
all, this method seemed effective in estimating the average 
treatment effect using the full power of the original dataset 
without selection bias. By using the stabilized weightings, 
treatment effects and their variances could be estimated sim-
ply using conventional modeling methods, with adjustments 
for any residual confounding.
Covariate adjustment using the propensity score
Covariate adjustment using the propensity score gave results 
consistent with other methods for all endpoints. Further 
adjustment was limited (outcome exacerbation rate was 
Table S2 Unadjusted results for study endpoints
Unmatched Exact matching Propensity score matching Stabilized IPTW 
pseudo-datasetRiRL algorithm Greedy algorithm
Ciclesonide 
(n=1382)
FP ICS 
(n=2682)
Ciclesonide 
(n=1244)
FP ICS 
(n=1244)
Ciclesonide 
(n=1321)
FP ICS 
(n=1321)
Ciclesonide 
(n=1323)
FP ICS 
(n=1323)
Ciclesonide 
(n=1380)
FP ICS 
(n=2683)
Severe exacerbations
 0 1240 (90) 2281 (85) 1123 (90) 1065 (86) 1187 (90) 1128 (85) 1189 (90) 1136 (86) 1242 (90) 2277 (85)
 ≥1 142 (10) 401 (15) 121 (10) 179 (14) 134 (10) 193 (15) 134 (10) 187 (14) 138 (10) 406 (15)
Risk-domain asthma 
control
1240 (90) 2281 (85) 1123 (90) 1065 (86) 1187 (90) 1128 (85) 1189 (90) 1136 (86) 1242 (90) 2277 (85)
Overall control 1180 (85) 1928 (72) 1075 (86) 947 (76) 1127 (85) 996 (75) 1129 (85) 983 (74) 1169 (85) 1951 (73)
Change in therapy 360 (26) 882 (33) 329 (26) 416 (33) 341 (26) 444 (34) 343 (26) 432 (33) 372 (27) 894 (33)
Note: Data are n (%).
Abbreviations: FP ICS, fine-particle inhaled corticosteroid; IPTW, inverse probability of treatment weighting; RiRL, Research in Real-Life.
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additionally adjusted for baseline exacerbations; outcome 
risk-domain asthma control and overall asthma control were 
additionally adjusted for baseline risk-domain asthma control 
status), but other adjustments (baseline SABA use, evidence of 
GERD) correlated strongly with the propensity score leading 
to collinearity in the model. As an exercise, we adjusted end-
point models for component baseline confounders rather than 
the propensity score and compared the results. Certainly for 
the exacerbation and risk-domain asthma control endpoints, 
there was very little difference in results between adjusting 
for the propensity score plus baseline exacerbation count 
and risk-domain asthma control status, respectively, than a 
full covariate list, but the propensity score adjustment made 
the models more parsimonious and simpler to reduce. There 
was more variation in results for the overall asthma control 
endpoint, but the fully adjusted model was very sensitive to 
adjustments and again, propensity score adjustment provided 
a simple and parsimonious option. When many potential 
confounders are involved, many of which may be collinear, 
the final model choice can be subjective. Thus, provided 
the propensity score is correctly specified, adjusting for the 
propensity score provides a simple, effective, and repeatable 
method to account for differences between treatment arms.
Interestingly, the propensity score was not a significant 
covariate in the model for therapy change; adjustments to the 
treatment effect could be made by adjusting for evidence of 
GERD and rhinitis and, for this endpoint, seemed the prefer-
able option. The nonsignificance of the propensity score in 
this model, and the general stability of the therapy change 
results across all analysis methods, suggests that this endpoint 
was quite robust and not greatly influenced by treatment bias.
Stratification by propensity score
This method would not be an appropriate choice in a study 
where the primary endpoint is exacerbation rate. A negative 
binomial model cannot be stratified (using PROC GEN-
MOD), and, whereas a Poisson model can be stratified, the 
unadjusted, stratified model took several hours to run, and 
there was insufficient memory to stratify and additionally 
adjust, even for one additional variable. Furthermore, the 
unadjusted stratified model gave identical results to the 
unmatched, unadjusted model. Stratification was possible 
and practical for the dichotomous endpoints.
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